Assertio (ASRT)
(Delayed Data from NSDQ)
$0.71 USD
0.00 (-0.49%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $0.70 -0.01 (-1.75%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ASRT 0.71 0.00(-0.49%)
Will ASRT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ASRT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASRT
New Strong Sell Stocks for July 8th
New Strong Sell Stocks for June 30th
ASRT: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for June 25th
New Strong Sell Stocks for June 18th
Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates
Other News for ASRT
Assertio Holdings (ASRT) Receives Reiterated Buy Rating with $3.50 Price Target | ASRT Stock News
Assertio Therapeutics: Buy Rating Affirmed Amid Strong ROLVEDON Growth and Positive Financial Outlook
Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, ...
Assertio Therapeutics’ Earnings Call: Mixed Results and Strategic Plans
Maxim Group Sticks to Its Buy Rating for Assertio Therapeutics (ASRT)